INVESTIGADORES
PASQUINI juana Maria
artículos
Título:
Intranasal administration of aTf protects and repairs the neonatal white matter after a cerebral hypoxic-ischemic event
Autor/es:
GUARDIA CLAUSI M, PAEZ PM, CAMPAGNONI AT, PASQUINI LA PASQUINI JM.
Revista:
GLIA
Editorial:
WILEY-LISS, DIV JOHN WILEY & SONS INC
Referencias:
Lugar: New York; Año: 2012 vol. 60 p. 1540 - 1554
ISSN:
0894-1491
Resumen:
ABSTRACT
Our previous studies showed that the intracerebral injection
of apotransferrin (aTf) attenuates white matter damage and
accelerates the remyelination process in a neonatal rat model
of cerebral hypoxia-ischemia (HI) injury. However, the intracerebral
injection of aTf might not be practical for clinical
treatments. Therefore, the development of less invasive techniques
capable of delivering aTf to the central nervous system
would clearly aid in its effective clinical use. In this
work, we have determined whether intranasal (iN) administration
of human aTf provides neuroprotection to the neonatal
mouse brain following a cerebral hypoxic?ischemic event.
Apotransferrin was infused into the naris of neonatal mice
and the HI insult was induced by right common carotid artery
ligation followed by exposure to low oxygen concentration.
Our results showed that aTf was successfully delivered
into the neonatal HI brain and detected in the olfactory bulb,
forebrain and posterior brain 30 min after inhalation. This
treatment successfully reduced white matter damage, neuronal
loss and astrogliosis in different brain regions and
enhanced the proliferation and survival of oligodendroglial
progenitor cells (OPCs) in the subventricular zone and corpus
callosum (CC). Additionally, using an in vitro hypoxic
model, we demonstrated that aTf prevents oligodendrocyte
progenitor cell death by promoting their differentiation. In
summary, these data suggest that iN administration of aTf
has the potential to be used for clinical treatment to protect
myelin and to induce remyelination in demyelinating
hypoxic?ischemic events in the neonatal brain.corpus
callosum (CC). Additionally, using an in vitro hypoxic
model, we demonstrated that aTf prevents oligodendrocyte
progenitor cell death by promoting their differentiation. In
summary, these data suggest that iN administration of aTf
has the potential to be used for clinical treatment to protect
myelin and to induce remyelination in demyelinating
hypoxic?ischemic events in the neonatal brain.(CC). Additionally, using an in vitro hypoxic
model, we demonstrated that aTf prevents oligodendrocyte
progenitor cell death by promoting their differentiation. In
summary, these data suggest that iN administration of aTf
has the potential to be used for clinical treatment to protect
myelin and to induce remyelination in demyelinating
hypoxic?ischemic events in the neonatal brain.